Bildkälla: Stockfoto

Active Biotech Q2 2023: New Focus on Myelofibrosis - Redeye

Active Biotech will move the focus of the clinical development of tasquinimod to myelofibrosis, which is an indication with a high unmet need and little competition. The overall strategy will be to continue relying on partners for the clinical development of all assets.

Active Biotech will move the focus of the clinical development of tasquinimod to myelofibrosis, which is an indication with a high unmet need and little competition. The overall strategy will be to continue relying on partners for the clinical development of all assets.
Börsvärldens nyhetsbrev
ANNONSER